Results 41 to 50 of about 1,359 (188)
Orthostatic hypotension: An overlooked but clinically decisive entity
Journal of the Indian Academy of Geriatrics, 2022 Orthostatic hypotension (OH) is defined as a drop of >20 mm Hg of systolic or >10 mm Hg of diastolic blood pressure (BP) within 3 min of standing from lying position. It is a common geriatric syndrome caused by impaired orthostatic response of BP.
Gunja Jain +3 more
doaj +1 more source
Prospects for Droxidopa in Neurogenic Orthostatic Hypotension [PDF]
Hypertension, 2015 See related article, pp 101–107 Neurogenic orthostatic hypotension (nOH) is a debilitating disorder defined by a sustained decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within 3 minutes of head-up tilt or standing.1 The disorder is associated with attenuated increases in plasma norepinephrine and peripheral
Julian M. Stewart, Amanda J. Ross
openaire +3 more sources
Psychogeriatrics, Volume 23, Issue 5, Page 752-762, September 2023., 2023 Background The real‐world status of satisfaction with medication for dementia with Lewy bodies (DLB) has not been elucidated. We assessed the satisfaction of patients with DLB, their caregivers, and their attending physicians (trios) with medication according to the clinical symptom domains of DLB.
Shunji Toya +4 more
wiley +1 more source
Chemistry, 2023 Tyrosine-containing pharmaceuticals’ (TPh) potential to inhibit SARS CoV-2 3-chymotrypsin-like proteases (3CLpro) and nonstructural protein 16 (NSP16) has been explored using docking studies, molecular dynamics simulations, and density functional theory.
Mohamed R. Elamin +2 more
doaj +1 more source
Accelerated approval drug labels often lack information for clinical decision‐making
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 43, Issue 4, Page 300-304, April 2023., 2023 Abstract Study objective We evaluated US Food and Drug Administration labels for drugs approved under the accelerated approval pathway and whether these labels contained in sufficient information regarding their accelerated approval. Design Retrospective, observational, cohort study.
Jeromie Ballreich +5 more
wiley +1 more source
Differences in Parkinson's disease treatment between neurology and other departments in Japan
Neurology and Clinical Neuroscience, Volume 11, Issue 2, Page 79-89, March 2023., 2023 Abstract Background Parkinson's disease is common in elderly people and is treated in the neurology department as well as in other departments. Recently, treatment options for Parkinson's disease have expanded; this complicates selection of the best treatment regimen.
Yoshio Tsuboi +5 more
wiley +1 more source
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 9, Issue 1, January‐March 2023., 2023 Abstract The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical Dementia Rating scale and Alzheimer's Disease Assessment Scale–Cognitive Subscale being among the ...
Marwan N. Sabbagh +9 more
wiley +1 more source
Acta Neurologica Scandinavica, Volume 2023, Issue 1, 2023., 2023 Objectives. Postural orthostatic tachycardia syndrome (POTS) is characterized by cardiovascular autonomic dysfunction of unknown etiology with high a prevalence of gastrointestinal symptoms. The aim of the present study was to examine sociodemographic, lifestyle, and nutritional factors as well as inflammatory markers in patients with POTS.
Hanna Tufvesson +5 more
wiley +1 more source
Accidental Overdose of Droxidopa in Parkinson's Disease-related Orthostatic Hypotension [PDF]
Movement Disorders Clinical Practice, 2016 Addie Patterson, Christopher W. Hess
openalex +3 more sources
Parkinson's Disease, Volume 2023, Issue 1, 2023., 2023 Prescription doses of levodopa in patients with advanced Parkinson’s disease (PD) are generally lower in Japan than in the United States or Europe, although Japanese guidelines for the management of PD recommend increasing the dosage as the disease progresses.
Atsushi Takeda +6 more
wiley +1 more source